Innophos, a leading international producer of nutritional specialty ingredients and custom formulated solutions, today announced the release of new clinical findings from ENovate Biolife highlighting OxyjunŽ, a premium branded extract of Terminalia arjuna. Extracted from the bark of the Arjuna tree, Terminalia arjuna has traditionally been used for cardio protection purposes. The findings from this latest human clinical trial demonstrate advanced benefits in the areas of cardiac output and perceived reduction in physical fatigue in study subjects.
CRANBURY, N.J., Jan. 12, 2023 /PRNewswire-PRWeb/ -- Innophos, a leading international producer of nutritional specialty ingredients and custom formulated solutions, today announced the release of new clinical findings from ENovate Biolife highlighting OxyjunŽ, a premium branded extract of Terminalia arjuna. Extracted from the bark of the Arjuna tree, Terminalia arjuna has traditionally been used for cardio protection purposes. The findings from this latest human clinical trial demonstrate advanced benefits in the areas of cardiac output and perceived reduction in physical fatigue in study subjects.
"Cardiac health is of the utmost importance for today's consumers, and we are excited about the beneficial findings of OxyjunŽ from this study," said Dr. Bruce Abedon, R&D Senior Manager at Innophos and co-author of the study. "As the exclusive licensed distributor of OxyjunŽ in North America, our team at Innophos is committed to providing the highest quality, science-backed products, and continuing our partnership with ENovate Biolife."
The new study, published in the peer-reviewed Journal of Multidisciplinary Health, featured 72 male and female subjects ranging in age from 30-70 years old that took 400 mg of OxyjunŽ daily for 56 days. Subjects were evaluated on both cardiac output based on left ventricular ejection fraction (the volume of blood flowing from the heart to the body with each beat) as well as their perceived level of physical fatigue based on a validated, multi-question Fatigue Severity Scale instrument.
Consumption of OxyjunŽ resulted in numerous improvements in the health of subjects including:
OxyjunŽ is a registered trademark of ENovate Biolife LLC.
*These statements have not been evaluated by the Food and Drug Administration. This ingredient is not intended to diagnose, treat, cure, or prevent any disease.
About Innophos Innophos is a leading international producer of specialty ingredient solutions that deliver far-reaching, versatile benefits for the food, health, nutrition, and industrial markets. We leverage our expertise in the science and technology of blending and formulating phosphate, mineral, enzyme, and botanical based ingredients to help our customers offer products that are tasty, healthy, nutritious, and economical. Headquartered in Cranbury, New Jersey, Innophos has manufacturing operations across the United States, in Canada, Mexico, a
Media Contact
Carrie Livingston, ColinKurtis, 8155198302, [email protected]
SOURCE Innophos
Advertisement
CRANBURY, N.J., Jan. 12, 2023 /PRNewswire-PRWeb/ -- Innophos, a leading international producer of nutritional specialty ingredients and custom formulated solutions, today announced the release of new clinical findings from ENovate Biolife highlighting OxyjunŽ, a premium branded extract of Terminalia arjuna. Extracted from the bark of the Arjuna tree, Terminalia arjuna has traditionally been used for cardio protection purposes. The findings from this latest human clinical trial demonstrate advanced benefits in the areas of cardiac output and perceived reduction in physical fatigue in study subjects.
Advertisement
"Cardiac health is of the utmost importance for today's consumers, and we are excited about the beneficial findings of OxyjunŽ from this study," said Dr. Bruce Abedon, R&D Senior Manager at Innophos and co-author of the study. "As the exclusive licensed distributor of OxyjunŽ in North America, our team at Innophos is committed to providing the highest quality, science-backed products, and continuing our partnership with ENovate Biolife."
The new study, published in the peer-reviewed Journal of Multidisciplinary Health, featured 72 male and female subjects ranging in age from 30-70 years old that took 400 mg of OxyjunŽ daily for 56 days. Subjects were evaluated on both cardiac output based on left ventricular ejection fraction (the volume of blood flowing from the heart to the body with each beat) as well as their perceived level of physical fatigue based on a validated, multi-question Fatigue Severity Scale instrument.
Consumption of OxyjunŽ resulted in numerous improvements in the health of subjects including:
- 6.28% increase in cardiac output (vs. 0.24% for placebo)
- 22.5% perceived reduction in physical fatigue (vs. 8.5% for placebo)
- No adverse events related to consumption of OxyjunŽ for any of the study participants
OxyjunŽ is a registered trademark of ENovate Biolife LLC.
*These statements have not been evaluated by the Food and Drug Administration. This ingredient is not intended to diagnose, treat, cure, or prevent any disease.
About Innophos Innophos is a leading international producer of specialty ingredient solutions that deliver far-reaching, versatile benefits for the food, health, nutrition, and industrial markets. We leverage our expertise in the science and technology of blending and formulating phosphate, mineral, enzyme, and botanical based ingredients to help our customers offer products that are tasty, healthy, nutritious, and economical. Headquartered in Cranbury, New Jersey, Innophos has manufacturing operations across the United States, in Canada, Mexico, a
Media Contact
Carrie Livingston, ColinKurtis, 8155198302, [email protected]
SOURCE Innophos
